Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kardigan, Inc.KARD · Entity 4569 | Chief Medical Officer | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kardigan, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,327 |
Ending reported balance
After 2026-06-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-17 · Conversion · Acquired 97,587 · Balance 135,543 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. Row 2 · 2026-06-17 · Grant · Acquired 47,784 · Balance 183,327 F2: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Conversion · Disposed 61,268 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Edelberg Family Ventures, LLC | 4,459,840 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,459,840 F3: Represents shares held by Edelberg Family Ventures, LLC. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.
F2: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.
F3: Represents shares held by Edelberg Family Ventures, LLC. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Kardigan, Inc. KARD · Entity 4569 | ConversionSeries B Preferred Stock · Derivative | 61,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-277907 · ownership.xml · derivative · entry 4 Edelberg Jay · CIK 0002138489 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Kardigan, Inc. KARD · Entity 4569 | GrantCommon Stock | 47,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-277907 · ownership.xml · nonDerivative · entry 2 Edelberg Jay · CIK 0002138489 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,327 F2 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC | Kardigan, Inc. KARD · Entity 4569 | ConversionCommon Stock | 97,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-277907 · ownership.xml · nonDerivative · entry 1 Edelberg Jay · CIK 0002138489 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.